ABS0532 VALIDATION OF HANDHELD ULTRASOUND DEVICES FOR POINT OF CARE USE IN RHEUMATOLOGY: ANALYSIS FOR ENTHESITIS

Background: Ultrasonography (US) has experienced a rapid evolution in rheumatology. Despite many advantages being repeatedly shown, several barriers persist, equipment cost being an important one. Hand-held US technology promises to substantially lower this cost. However, before it can be used explicitly for rheumatology, its performance must be validated against gold-standard devices. Objectives: We aim to test the concurrent validity of a handheld US device versus a gold-standard device to detect characteristic features of enthesitis. Methods: Peripheral PsA patients with at least one tender and swollen joint were included. Each patient had consecutive US examinations using a handheld (Clarius Mobile Health Inc, HD3 L15 scanner) and a gold-standard US device (GE LogicE9-E10) for detecting elementary lesions of enthesitis (hypoechogenicity, thickening, erosion, enthesophyte, calcification and Doppler). Supraspinatus, triceps, common extensor tendon, quadriceps, patellar ligament (origin and insertion), Achilles tendon and plantar fascia entheses were evaluated. B-mode and power Doppler images were saved for each site and lesion. Every image was given a unique identifier number after collection for blinding purpose. A random order slide show was conducted for scoring, irrespective of the machine, anatomical site or patient, to ensure blindness. Scoring was done using previously validated methods. The inflammation score was obtained by summing hypoechogenicity, thickening, and Doppler scores, and the chronicity score was obtained by summing erosion, enthesophyte, and calcification scores. The total enthesitis score was determined by the sum of the inflammation and chronicity scores. Cohen's kappa coefficient was calculated to test the agreement for elementary lesions of enthesitis, in addition to intraclass correlation analysis. Results: Thirty patients were included in the study, scanning 480 entheses. On the day of the US, 19 (63.3%) patients had at least one tender enthesis on physical examination. The median (IQR) SPARCC enthesitis score was 1(0-5.0). The agreement was substantial (see Table 1) for enthesophytes and erosions; moderate for thickening, Doppler and hypoechogenicity; and fair for calcification (Table 1). A very strong agreement was detected between the devices both for the inflammation, chronicity and total enthesitis scores (ICC (intraclass correlation) and p values: inflammation: 0.909 and <0.001; chronicity: 0.917 and <0.001; total: 0.935 and <0.001). Conclusion: In this analysis, the handheld US device with L15 scanner showed moderate-substantial agreement to detect elementary lesions of enthesitis, with the exception of calcifications. In addition, a very strong consistency was found between the devices in inflammation, chronicity and total enthesitis scores, which enable physicians to evaluate enthesitis as a whole. These results encourage the use of handheld US devices for wider use. Table 1. The frequency, kappa and percent absolute agreement of elementary lesions in enthesitis areas. REFERENCES: NIL . Acknowledgements: NIL . Disclosure of Interests: Seyyid Acikgoz: None declared, Ummugulsum Gazel: None declared, Suharsh Shah Full-time employee at Novartis Pharmaceuticals Canada Inc, Marie Maguin Full-time employee at Novartis Pharmaceuticals Canada Inc, Rohan Machhar Full-time employee at Novartis Pharmaceuticals Canada Inc, Patrick Leclerc Novartis Employee, Lihi Eder Abbvie, Pfizer, UCB, Fresenius, Novartis, J&J, Abbvie, Pfizer, UCB, Novartis, Eli Lilly, BMS, Moonlake, J&J, Abbvie, Pfizer, UCB, Novartis, Eli Lilly, J&J, Fresenius Kabi, Gurjit Kaeley Research grants from Novartis, Gilead/ Galapagos, BMS,Janssen, Abbvie, Sibel Aydin received payment or honoraria for lectures, presentations, speaker's bureaus, manuscript writing, or educational events from Abbvie, Jannsen, Novartis, Pfizer, and UCB, received payment or honoraria for lectures, presentations, speaker's bureaus, manuscript writing, or educational events from Abbvie, Jannsen, Novartis, Pfizer, and UCB, stock options in Clarius, received consultant's fees from Abbvie, Celgene, Eli Lilly, Novartis, Pfizer, Sanofi, and UCB, received grants or contracts from Abbvie, Celgene, Eli Lilly, Jannsen, Novartis, Pfizer, Sanofi, and UCB. © The Authors 2025. This abstract is an open access article published in Annals of Rheumatic Diseases under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Neither EULAR nor the publisher make any representation as to the accuracy of the content. The authors are solely responsible for the content in their abstract including accuracy of the facts, statements, results, conclusion, citing resources etc.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.